Unicycive Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Stockholders??? Equity (Details)

Stockholders’ Equity (Details) - USD ($)			12 Months Ended
Stockholders’ Equity (Details) - USD ($)	Jul. 11, 2023	Jul. 31, 2021	Dec. 31, 2025	Aug. 26, 2025	Jun. 30, 2025	Jun. 11, 2025	Feb. 18, 2025	Dec. 31, 2024	Dec. 19, 2024	Dec. 18, 2024	Dec. 11, 2024	Oct. 31, 2024	Oct. 09, 2024	Aug. 14, 2024	Jul. 29, 2024	Jul. 25, 2024	Jul. 23, 2024	Jul. 05, 2024	Jun. 25, 2024	Mar. 26, 2024	Mar. 13, 2024
Stockholders’ Equity Deficit [Line Items]
Common stock, shares authorized			400,000,000					400,000,000
Common stock, par value (in Dollars per share)			$ 0.001					$ 0.001
Common stock share issued			22,114,245					11,384,236
Common stock price (in Dollars per share)		$ 50	$ 1,000
Shares of common stock	43,649		73,691
Convertible debt shares granted			18,419
Warrant [Member]
Stockholders’ Equity Deficit [Line Items]
Shares warrants		400,000
Common stock price (in Dollars per share)		$ 0.1
Warrants term		5 years	5 years
Exercise price per warrant (in Dollars per share)		$ 60	$ 60
Purchase of additional warrants		60,000
Proceeds of warrants (in Dollars)		$ 7,500
Series A-2 Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued											462,455									285,000
Conversion of the shares series preferred stock	43,649										2,266.03									1,396.5
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued																		4,211,800
Series B-2 Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued						300,000			300,300	144,100		43,800
Conversion of the shares series preferred stock						3,000			3,003	1,441		438						7,882
Series A-3 Warrants and Received [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued					277,000
Conversion of the shares series preferred stock					1,500,000
IPO [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued		500,000
Common Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Common stock share issued				652,900			140,000						550,000	350,200	135,900	375,600	355,000		595,600
Common stock price (in Dollars per share)		$ 49.9																			$ 1,000
Conversion of the shares series preferred stock	1,951,621
Preferred Stock [Member] \| Series A-2 Prime Preferred Stock [Member]
Stockholders’ Equity Deficit [Line Items]
Conversion of the shares series preferred stock				3,199.21			686						2,695	1,715.98	665.91	1,840.44	1,739.5		2,918.44